ERBB2 and gastric cancer: We retrospectively investigated the medical records of the patients with HER2 positive (immunohistochemistry (IHC) 3+ or IHC2+/fluorescence in-situ hybridization (FISH) positive) stage IV gastric cancer who were treated with trastuzumab-based chemotherapy as the first line treatment from October 2011 to April 2017.